Log In Sign up
The largest database of trusted experimental protocols

Pd l1 ihc 22c3 pharmdx antibody clone 22c3

Manufactured by Agilent Technologies
Visit Supplier
Sourced in United States

The PD-L1 IHC 22C3 pharmDx antibody (clone 22C3) is a laboratory reagent used for the detection of the PD-L1 protein in tissue samples. It is designed for use with immunohistochemistry (IHC) techniques.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

PD-L1 IHC 22C3 pharmDx PD-L1- (clone 22C3 pharmDx, PD‐L1 22C3 pharmDx antibody PD-L1 antibody clone 22C3 PD-L1 (clone 22C3, PharmDx antibody (clone 22C3; 22C3 PD-L1 antibody 22C3 pharmDx antibody 22C3 pharmDx Antibody clone 22C3

2 protocols using pd l1 ihc 22c3 pharmdx antibody clone 22c3

1

PD-L1 Expression Analysis in Lung Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
PD-L1 expression in the lung cancer specimen was analyzed by immunohistochemical staining using the PD-L1 IHC 22C3 pharmDx antibody (clone 22C3, Dako North America, Inc., Carpinteria, CA, USA). The antibody was applied according to DAKO-recommended detection methods. PD-L1 expression in tumor cells was scored as the percentage of stained cells.
Sato R., Imamura K., Sakata S., Ikeda T., Horio Y., Iyama S., Akaike K., Hamada S., Jodai T., Nakashima K., Ishizuka S., Sato N., Saruwatari K., Saeki S., Tomita Y, & Sakagami T. (2019). Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies. Journal of Clinical Medicine, 8(6), 762.
+ Open protocol
+ Expand
2

PD-L1 Expression Analysis in Lung Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
PD-L1 expression in the lung cancer specimen was analyzed by immunohistochemical staining using the PD-L1 IHC 22C3 pharmDx antibody (clone 22C3 (Dako North America, Inc., Carpinteria, CA, USA)). The antibody was applied according to DAKO-recommended detection methods. PD-L1 expression in tumor cells was scored as the percentage of stained cells.
Saruwatari K., Sato R., Nakane S., Sakata S., Takamatsu K., Jodai T., Mito R., Horio Y., Saeki S., Tomita Y, & Sakagami T. (2019). The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients. Cancers, 11(2), 140.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!